Azitra, Inc. is pioneering genetically engineered bacterial therapies targeting rare and treatment-resistant skin diseases leveraging a proprietary microbial library enhanced by AI-driven drug discovery. Its lead candidates ATR-12 and ATR-04 have progressed into early-phase clinical trials with orphan designations and initial safety data reported, underscoring scientific validation. However, financials reveal zero revenues by FY2025 and over $11 million net losses annually, reflecting the heavy development investment characteristic of early-stage biopharma. Limited cash on hand intensifies funding risk, highlighting the importance of clinical milestones and capital raises for long-term viability.